厄贝沙坦氢氯噻嗪片治疗老年单纯性收缩期高血压的疗效观察

目的探讨厄贝沙坦氢氯噻嗪片(安博诺)治疗老年单纯性收缩期高血压患者的临床效果。方法2010年1月—2012年12月诊治、符合入组标准的老年单纯性收缩期高血压患者78例,随机分为2组,其中接受安博诺治疗的患者为观察组(39例,剔除4例),接受依那普利联合氢氯噻嗪联合降压治疗的患者为对照组(39例,剔除3例)。观察2组患者临床治疗疗效、血压、脉压及电解质变化情况并进行比较,同时记录不良反应。结果观察组患者总有效率为91.4%(32/35),与对照组的91.6%(33/36)比较无明显差异(P>0.05)。2组患者的收缩压、舒张压及脉压差均随着时间延长而逐渐下降,但2组2、4、6、8周组内比较差异无统计学意义(P>0.05);与治疗前比较,2组治疗后3个指标均显著改善(对照组治疗后2周舒张压除外,P<0.05)。2组患者心率比较亦未见无明显的变化(P>0.05)。除对照组治疗后血K⁺水平轻度下降外(P<0.05),2组治疗前后电解质、肝肾功能无明显变化(P>0.05)。观察组不良事件发生率为5.7%(2/35),对照组不良事件发生率为8.3%(3/36),差异亦无统计学意义(P>0.05)。结论安博诺治疗老年单纯性收缩期高血压能够有效控制血压,临床疗效显著,不良反应发生率低,值得临床推广应用。

Clinical effect of coaprovel in the treatment of elder patients with isolated systolic hypertension

Objective To investigate the clinical effect of eoaprovel in the treatment of elder patients with isolated systolic hypertension （ISH）. Methods From January 2010 to December 2012, elderly patients meets the standard of diagnosis and treatment of isolated systolic hypertension （78 cases） were randomly divided into 2 groups, observation group were received the Abono treatment （39 cases, 4 cases were excluded） , control group were received enalapril and hydrochlorothiazide combination therapy （39 cases, 3 cases were excluded）. Clinical curative effect, blood pressure, pulse pressure and electrolyte changes and adverse reactions of 2 groups of patients were recorded and compared. Results Patients in the observation group~ total effective rate was 91.4% （32/35）, and in control group was 91.6% （33/36） , there were no significant differ- ences （ P 〉 0.05 ）. 2 groups of patients with systolic pressure, diastolic pressure and pulse pressure increased along with the time increased, but the 2 groups＇2, 4, 6, 8 weeks intra-group comparison revealed no significant difference （ P 〉 0.05 ） ; compared with before treatment, after 2,4,6,8 weeks treatment, three indicators of the 2 groups were significantly improved （except DBP after 2 weeks in control group, P 〈 0.05）. Heart rate of the 2 groups of patients also had no obvious change （P 〉 O. 05）. After treatment, except the control group＇s blood K ~ level was mild declined （ P 〈 0.05 ） , before and after treatment, electrolyte, liver and kidney function of the 2 groups had no significant changes （ P 〉 0.05 ）. The observation groupg incidence of adverse events was 5.7% （2/35）, the control groupg incidence of adverse events was 8.3% （3/36）, the difference had no statistical significance （ P 〉 O. 05）. Conclusion In the treatment of elder ISH patients, coaprovel can effectively control blood pressure, had great curative effects, the adverse reactions rate was low. Hence, it was worthy of clinical promotion.